Barclays Maintains Equal-Weight on OptimizeRx, Lowers Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Stephanie Davis maintains an Equal-Weight rating on OptimizeRx (NASDAQ:OPRX) but lowers the price target from $15 to $11.
August 12, 2024 | 12:24 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Barclays analyst Stephanie Davis maintains an Equal-Weight rating on OptimizeRx but lowers the price target from $15 to $11.
The lowered price target from $15 to $11 by Barclays suggests a less optimistic outlook for OptimizeRx, which could negatively impact investor sentiment and short-term stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100